Drugs / AutoSynVax™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02992977 | Jan 2017 → Dec 2018 | — | Agenus Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-04-05 | Agenus Inc. | Results Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™ agenusbio.com ↗
Preclinical data presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting show ASV to be active and synergistic with checkpoint blockade. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-04-05 | Agenus Inc. | Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™ agenusbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AutoSynVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02992977 ↗ |
| Modality | Vaccine | “AutoSynVax™ vaccine” NCT02992977 ↗ |
| Route | Subcutaneous | “every other week subcutaneous injection of 240 μg AutoSynVax™ vaccine” NCT02992977 ↗ |